Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Instagram Outage Disrupts Thousands of U.S. Users 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
-- Ablexis Looks Forward to Establishing Additional Non-Exclusive Partnerships in 2017 --
BURLINGAME, Calif., Feb. 14, 2017 -- Ablexis, LLC today announced a licensing agreement for its AlivaMab Mouse technology with Janssen Biotech, Inc. (Janssen). The perpetual, non-exclusive license provides Janssen access to the AlivaMab Mouse platform and broad rights to use the AlivaMab Mouse for antibody drug discovery and development. Ablexis will receive an eight-figure up-front payment.
“Ablexis is pleased to add Janssen to the growing list of companies that have licensed the AlivaMab Mouse,” said Larry Green, Ph.D., Chief Executive Officer of Ablexis. “This license further affirms the recognition by the world’s leading pharmaceutical companies of the power of the AlivaMab Mouse for rapid and efficient discovery of antibody drug candidates that meet target product profiles for activity, specificity and developability. Ablexis remains dedicated to making the AlivaMab Mouse broadly available for antibody drug discovery through flexible partnering strategies.”
About Ablexis, LLC
Ablexis, LLC created and commercializes the AlivaMab Mouse technology, a unique next-generation transgenic mouse platform for human therapeutic antibody discovery. Ablexis has announced non-exclusive licensing of the AlivaMab Mouse technology to multiple global pharmaceutical companies and continues making the AlivaMab Mouse available via non-exclusive licenses. The company was founded in 2009 and is based in Burlingame, California; more information can be found by visiting the Company’s website at www.ablexis.com.
Ablexis Corporate Contact: Ablexis, LLC Larry Green, (415) 967-1220 [email protected] Ablexis Media Contact: Red House Communications Denise Powell, (510) 703-9491 [email protected]
